Literature DB >> 10453882

Advances in the treatment of malignant pleural mesothelioma.

D H Sterman1, L R Kaiser, S M Albelda.   

Abstract

Malignant pleural mesothelioma is a neoplasm that is commonly fatal and for which there are no widely accepted curative approaches. Mesothelioma is unresponsive to most chemotherapy and radiotherapy regimens, and it typically recurs even after the most aggressive attempts at surgical resection. Multimodality approaches have been of some benefit in prolonging survival of very highly selected subgroups of patients, but they have had a relatively small impact on the majority of the patients diagnosed with this disease. As the incidence of pleural mesothelioma peaks in the United States and Europe over the next 10 to 20 years, new therapeutic measures will be necessary. This review will discuss the roles of chemotherapy, radiotherapy, surgery, and combined modality approaches in the treatment of pleural mesothelioma, as well as scientific advances made in the past decade that have led to the development of experimental techniques, such as photodynamic therapy, immunotherapy, and gene therapy, that are currently undergoing human clinical trials. These promising new avenues may modify the therapeutic nihilism that is rampant among clinicians dealing with mesothelioma.

Entities:  

Mesh:

Year:  1999        PMID: 10453882     DOI: 10.1378/chest.116.2.504

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  21 in total

1.  Phase II study of intravenous Doxil in malignant pleural mesothelioma.

Authors:  Y Oh; R Perez-Soler; F V Fossella; B S Glisson; J Kurie; G L Walsh; M Truong; D M Shin
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

2.  Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems.

Authors:  J G Edwards; K R Abrams; J N Leverment; T J Spyt; D A Waller; K J O'Byrne
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

3.  Conference report--gene therapy and lung cancer--no time to wait.

Authors:  Sara M Mariani
Journal:  MedGenMed       Date:  2004-07-16

Review 4.  Lung cancer * 8: Management of malignant mesothelioma.

Authors:  C Parker; E Neville
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

Review 5.  Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma.

Authors:  Michael Kent; David Rice; Raja Flores
Journal:  Curr Treat Options Oncol       Date:  2008-08-29

6.  Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso.

Authors:  Patricia J Hollen; Richard J Gralla; Astra M Liepa; James T Symanowski; James J Rusthoven
Journal:  Support Care Cancer       Date:  2005-07-06       Impact factor: 3.603

7.  Comparative genomic hybridisation in malignant deciduoid mesothelioma.

Authors:  A Scattone; A Pennella; M Gentile; M Musti; P Nazzaro; A L Buonadonna; A Marzullo; D Cavone; L Pollice; G Serio
Journal:  J Clin Pathol       Date:  2006-03-28       Impact factor: 3.411

8.  Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia.

Authors:  Mustafa Altinbas; Ozlem Er; Metin Ozkan; Hasan Senol Coskun; Inci Gulmez; Eyup Ekici; Bunyamin Kaplan; Bulent Eser; Mustafa Ozesmi
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

9.  Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.

Authors:  Ying Wang; Arun K Rishi; Vineshkumar T Puliyappadamba; Sunita Sharma; Huanjie Yang; Adi Tarca; Q Ping Dou; Fulvio Lonardo; John C Ruckdeschel; Harvey I Pass; Anil Wali
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-04       Impact factor: 3.333

10.  Long-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies.

Authors:  O Monneuse; A C Beaujard; B Guibert; F N Gilly; P Mulsant; P Y Carry; M Benoit; O Glehen
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.